Hepatitis Monthly

Published by: Kowsar

Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection

Ergenekon Karagoz 1 , * and Alpaslan Tanoglu 2
Authors Information
1 Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey
2 GATA Haydarpasa Training Hospital, Department of Gastroenterology, Istanbul, Turkey
Article information
  • Hepatitis Monthly: April 2017, 17 (4); e12293
  • Published Online: March 8, 2017
  • Article Type: Review Article
  • Received: March 4, 2016
  • Revised: February 8, 2017
  • Accepted: February 10, 2017
  • DOI: 10.5812/hepatmon.36112

To Cite: Karagoz E, Tanoglu A. Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection, Hepat Mon. 2017 ; 17(4):e12293. doi: 10.5812/hepatmon.36112.

Abstract
Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Footnote
References
  • 1. Zhang YM, Yang YD, Jia HY, Zeng LY, Yu W, Zhou N, et al. HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions. World J Gastroenterol. 2014; 20(15): 4407-13[DOI][PubMed]
  • 2. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004; 115(2): 217-22[PubMed]
  • 3. Maylin S, Boyd A, Delaugerre C, Zoulim F, Lavocat F, Simon F, et al. Comparison between Elecsys HBsAg II and Architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients co-infected with HIV and hepatitis B virus. Clin Vaccine Immunol. 2011; -11
  • 4. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012; 61 Suppl 1-17[DOI][PubMed]
  • 5. Karagoz E. Do hepatic flares really promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance? Hepatol Res. 2016; 46(7): 719[DOI][PubMed]
  • 6. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007; 133(3): 843-52[DOI][PubMed]
  • 7. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010; 51(6): 1933-44[DOI][PubMed]
  • 8. Ganji A, Esmaeilzadeh A, Ghafarzadegan K, Helalat H, Rafatpanah H, Mokhtarifar A. Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV. Hepat Mon. 2011; 11(5): 342-5[PubMed]
  • 9. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010; 52(4): 514-22[DOI][PubMed]
  • 10. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010; 52(4): 508-13[DOI][PubMed]
  • 11. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010; 52(4): 1232-41[DOI][PubMed]
  • 12. Ramachandran J, Ismail AM, Chawla G, Fletcher GJ, Goel A, Eapen CE, et al. Serum HBsAg quantification in treatment-naive Indian patients with chronic hepatitis B. Indian J Gastroenterol. 2014; 33(2): 131-5[DOI][PubMed]
  • 13. Chung KH, Kim W, Kim BG, Lee HY, Jin E, Cho Y, et al. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay. Gut Liver. 2015; 9(5): 657-64[DOI][PubMed]
  • 14. Jia W, Qi X, Ji YY, Xun YH, Wang H, Zhang WH, et al. Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China. Hepat Mon. 2015; 15(8)[DOI][PubMed]
  • 15. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010; 139(2): 483-90[DOI][PubMed]
  • 16. Park H, Lee JM, Seo JH, Kim HS, Ahn SH, Kim DY, et al. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver Int. 2012; 32(5): 796-802[DOI][PubMed]
  • 17. Sali S, Sharafi H, Alavian SH, Alavian SM, Etesam F, Salimi S, et al. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state? Diagn Microbiol Infect Dis. 2015; 82(2): 114-9[DOI][PubMed]
  • 18. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013; 58(3): 872-80[DOI][PubMed]
  • 19. Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol. 2013; 59(6): 1153-9[DOI][PubMed]
  • 20. Antaki N, Zeidane N, Alhaj N, Hadad M, Baroudi O, Antaki F, et al. HBsAg titers in the different phases of hepatitis B infection in Syrian patients. J Clin Virol. 2012; 53(1): 60-4[DOI][PubMed]
  • 21. Alghamdi A, Aref N, El-Hazmi M, Al-Hamoudi W, Alswat K, Helmy A, et al. Correlation between hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol. 2013; 19(6): 252-7[DOI][PubMed]
  • 22. Gunal O, Barut S, Etikan I, Duygu F, Tuncel U, Sunbul M. Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection. Turk J Gastroenterol. 2014; 25 Suppl 1: 142-6[DOI][PubMed]
  • 23. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011; 141(2): 517-25[DOI][PubMed]
  • 24. Arai M, Togo S, Kanda T, Fujiwara K, Imazeki F, Yokosuka O. Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance. Eur J Gastroenterol Hepatol. 2012; 24(4): 414-8[DOI][PubMed]
  • 25. Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, et al. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology. 2016; 64(2): 381-9[DOI][PubMed]
  • 26. Vigano M, Lampertico P. Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi J Gastroenterol. 2012; 18(2): 81-6[DOI][PubMed]
  • 27. Chan HLY, Wong GLH, Tse CH, Chan HY, Wong VWS. 360 Definition of Inactive Hepatitis B Carrier by Serum Hbsag and Hbv DNA Levels – a Long-Term Follow-up Study on Hbsag Seroclearance. J Hepatol. 2011; 54-5[DOI]
  • 28. Yakut M, Bektas M, Seven G, Kabaçam G, Karatayli E, Karatayli S, et al. 398 Characterization of the Inactive Hbsag Carrier State with 3 Year Follow-Up. J Hepatol. 2011; 54[DOI]
  • 29. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, et al. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: a follow-up study of an elderly cohort. Kaohsiung J Med Sci. 2015; 31(2): 102-7[DOI][PubMed]
  • 30. Demiroren K, Kocamaz H, Dogan Y. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B. Turk J Gastroenterol. 2015; 26(1): 36-41[DOI][PubMed]
  • 31. Xun YH, Zang GQ, Guo JC, Yu XL, Liu H, Xiang J, et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol. 2013; 28(11): 1746-55[DOI][PubMed]
  • 32. Farnik H, Lange CM, Hofmann WP, Berger A, Allwinn R, Welker MW, et al. Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. J Clin Virol. 2011; 52(3): 204-9[DOI][PubMed]
  • 33. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012; 142(5): 1140-1149 e3[DOI][PubMed]
  • 34. Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, et al. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol. 2014; 20(24): 7686-95[DOI][PubMed]
  • 35. Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014; 61(3): 515-22[DOI][PubMed]
  • 36. Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther. 2010; 15(8): 1133-9[DOI][PubMed]
  • 37. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009; 49(4): 1141-50[DOI][PubMed]
  • 38. Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2013; 7(2): 429-36[DOI][PubMed]
  • 39. Gane E, Jia JD, Han KH, Tanwandee T, Chuang WL, Marcellin P, et al. 69 neptune study: On-treatment hbsag level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in hbeag-positive patients. J Hepatol. 2011; 54
  • 40. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010; 52(2): 454-61[DOI][PubMed]
  • 41. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology. 2011; 53(3): 1054-5[DOI][PubMed]
  • 42. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int. 2015; 35 Suppl 1: 82-90[DOI][PubMed]
  • 43. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009; 49(4): 1151-7[DOI][PubMed]
  • 44. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res. 1994; 23(3-4): 251-7[PubMed]
  • 45. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011; 54(3): 449-54[DOI][PubMed]
  • 46. Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, et al. Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015; 62(1): 56-63[DOI][PubMed]
  • 47. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010; 52(5): 1611-20[DOI][PubMed]
  • 48. Lee JH, Kim SJ, Ahn SH, Lee J, Park Y, Kim HS. Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg. J Clin Pathol. 2010; 63(11): 1027-31[DOI][PubMed]
  • 49. Kim JH, Choi YJ, Moon HW, Ko SY, Choe WH, Kwon SY. HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. Clin Mol Hepatol. 2013; 19(4): 409-16[DOI][PubMed]
  • 50. Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. 2011; 106(10): 1766-73[DOI][PubMed]
  • 51. Gramenzi A, Loggi E, Micco L, Cursaro C, Fiorino S, Galli S, et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J Viral Hepat. 2011; 18(10)-74[DOI][PubMed]
  • 52. Kandemir OD, Gultekin O, Unlu S. Kinetics of hepatitis B surface antigen with nucleo(s)tide analogues. 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015. 2015;
  • 53. Bakhshizadeh F, Hekmat S, Keshvari M, Alavian SM, Mostafavi E, Keivani H, et al. Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B. Hepat Mon. 2015; 15(5)[DOI][PubMed]
  • 54. Zhang XLLG, Huang ZY. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen negative patients in Changzhou China. 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015. 2015;
  • 55. Chen CLC, Hung C, Hu T, Wang J, Lu S. Combination of age and hepatitis B surface antigen levels in predicting hbv relapse after cessation of entecavir treatment. 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015. 2015;
  • 56. Yu HLK, Hsu P. Changes of hepatitis B surface antigen levels in chronic hepatitis B patients with telbivudine treatment for more than 2 years. 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015. 2015;
  • 57. Cheng-Yuan Peng HC, Wen-Pang S, Chia-Hsin. L. , Po-Heng C, Sheng-Hung C. Kinetics of quantitative serum hbsag decline during seven yearsof nucleos(t)ide analogue therapy in chronic hepatitis B patients. 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015. 2015;
  • 58. Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis. 2010; 202(1): 86-92[DOI][PubMed]
  • 59. Xie QCH, Zhang NP, Qi X, Chen L, Guo S. Addition of peginterferon ALFA 2B during long term nucleos(t)ide analogue therapy increases HBEAG seroconversion and hbsag decline-week 48 results from a multicenter randomized controlled trial (pegon study). 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015.
  • 60. Chan HLYK, Papatheodoridis GYMF, Chien RN, Kwan P. Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB). 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015. 2015;
  • 61. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011; 140(1): 132-43[DOI][PubMed]
  • 62. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176): 1221-8[DOI][PubMed]
  • 63. Wu D, Han M, Ning Q. An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: the future of chronic hepatitis B? J Hepatol. 2015; 62(1): 240-1[DOI][PubMed]
  • 64. Li G, Jiang G, Lu J, Chen S, Cui L, Jiao J, et al. Inhibition of hepatitis B virus cccDNA by siRNA in transgenic mice. Cell Biochem Biophys. 2014; 69(3): 649-54[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments